Photo of David Magnusson
Lokon Pharma's Pipeline
Lokon Pharma focuses on the development of LOAd therapy for different types of cancer and in combination with other cancer therapeutics including chemotherapy and checkpoint blockade antibody therapy. The LOAd family includes a range of novel oncolytic viruses that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).
Phase I/II clinical trials to evaluate the safety and efficacy of LOAd703 are currently ongoing in the US and Sweden. The indication in the US study (NCT02705196) is pancreatic ductal adenocarcinoma (PDAC) while the trial in Sweden (NCT03225989) treats PDAC, ovarian cancer, colorectal cancer and biliary cancer patients.
A phase I/II clinical trial to evaluate the safety and efficacy of LOAd703 in combination with the checkpoint inhibitor atezolizumab will begin in early 2020 to treat malignant melanoma (NCT04123470).